Versatile biomimetic nanomedicine for treating cancer and inflammation disease-Reference-Cited by-同舟云学术

Versatile biomimetic nanomedicine for treating cancer and inflammation disease

Published:2023-04-01 Issue:2 Volume:3 Page:123-151
ISSN:2749-9642
Container-title:Medical Review
language:en
Short-container-title:

Author:

Zhao Zhiwen¹²,Wang Dangge¹²³^ORCID,Li Yaping¹²⁴^ORCID

Affiliation:

1. State Key Laboratory of Drug Research & Center of Pharmaceutics , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai , China

2. University of Chinese Academy of Sciences , Beijing , China

3. Yantai Key Laboratory of Nanomedicine & Advanced Preparations , Yantai Institute of Materia Medica , Yantai , China

4. Shandong Laboratory of Yantai Drug Discovery , Bohai Rim Advanced Research Institute for Drug Discovery , Yantai , China

Abstract

Abstract Nanosized drug delivery systems (NDDSs) have emerged as a powerful tool to optimize drug delivery in complex diseases, including cancer and inflammation. However, the therapeutic effect of NDDSs is still far from satisfactory due to their poor circulation time, low delivery efficiency, and innate toxicity. Fortunately, biomimetic approaches offer new opportunities to develop nanomedicine, which is derived from a variety of native biomolecules including cells, exosomes, bacteria, and so on. Since inheriting the superior biocompatibility and versatile functions of natural materials, biomimetic nanomedicine can mimic biological processes, prolong blood circulation, and lower immunogenicity, serving as a desired platform for precise drug delivery for treating cancer and inflammatory disease. In this review, we outline recent advances in biomimetic NDDSs, which consist of two concepts: biomimetic exterior camouflage and bioidentical molecule construction. We summarize engineering strategies that further functionalized current biomimetic NDDSs. A series of functional biomimetic NDDSs created by our group are introduced. We conclude with an outlook on remaining challenges and possible directions for biomimetic NDDSs. We hope that better technologies can be inspired and invented to advance drug delivery systems for cancer and inflammation therapy.

Funder

National Key R&D Program of China

National Natural Science Foundation of China

Youth Innovation Promotion Association of CAS

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/mr-2022-0046/pdf

Reference151 articles.

1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA A Cancer J Clin 2020;70:7–30. https://doi.org/10.3322/caac.21590.

2. Vinay, DS, Ryan, EP, Pawelec, G, Talib, WH, Stagg, J, Elkord, E, et al.. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015;35:S185–98. https://doi.org/10.1016/j.semcancer.2015.03.004.

3. Arnedos, M, Vicier, C, Loi, S, Lefebvre, C, Michiels, S, Bonnefoi, H, et al.. Precision medicine for metastatic breast cancer--limitations and solutions. Nat Rev Clin Oncol 2015;12:693–704. https://doi.org/10.1038/nrclinonc.2015.123.

4. Zhang, Y, Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807–21. https://doi.org/10.1038/s41423-020-0488-6.

5. Galon, J, Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197–218. https://doi.org/10.1038/s41573-018-0007-y.